Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma(MM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02955550
What this trial is testing

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Celularity Incorporated 15
Early research (Phase 1)Looking for participantsNCT07003568
What this trial is testing

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Early research (Phase 1)Not Yet RecruitingNCT07735546
What this trial is testing

UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma (MM)
Umoja Biopharma 100
Early research (Phase 1)Looking for participantsNCT07003555
What this trial is testing

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Testing effectiveness (Phase 2)Study completedNCT02185820
What this trial is testing

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 57
Early research (Phase 1)Study completedNCT02431208
What this trial is testing

Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Hoffmann-La Roche 85
Early research (Phase 1)Study completedNCT01344876
What this trial is testing

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaAcute Myeloid Leukemia+2 more
Otsuka Pharmaceutical Co., Ltd. 20
Early research (Phase 1)Looking for participantsNCT07409246
What this trial is testing

Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
AbbVie 127
Early research (Phase 1)Study completedNCT01497093
What this trial is testing

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 34
Early research (Phase 1)Ended earlyNCT03465540
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Who this might be right for
Multiple MyelomaAcute Myeloid LeukemiaNon-Hodgkins Lymphoma+4 more
Amgen 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04094961
What this trial is testing

Ixazomib + Pomalidomide + Dexamethasone In MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in Relapse
Omar Nadeem, MD 52
Very early researchUnknownNCT04626752
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 50
Testing effectiveness (Phase 2)UnknownNCT05509530
What this trial is testing

Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)

Who this might be right for
Multiple Myeloma
Xuzhou Medical University 30
Testing effectiveness (Phase 2)Ended earlyNCT04150965
What this trial is testing

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Who this might be right for
Multiple MyelomaRelapsed Refractory Multiple Myeloma
Multiple Myeloma Research Consortium 14
Testing effectiveness (Phase 2)Ended earlyNCT00648739
What this trial is testing

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaMultiple Myeloma
Alexion Pharmaceuticals, Inc. 26
Early research (Phase 1)Study completedNCT00710528
What this trial is testing

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Acute Myeloid Leukemia (AML)+1 more
Gilead Sciences 192
Testing effectiveness (Phase 2)Ended earlyNCT01695330
What this trial is testing

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Who this might be right for
Multiple Myeloma
Oncotherapeutics 5
Testing effectiveness (Phase 2)UnknownNCT05749133
What this trial is testing

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
XuYan 18
Testing effectiveness (Phase 2)Study completedNCT02206503
What this trial is testing

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 13
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Next Page